Duality Advisers’s Abiomed Inc ABMD Stock Holding History

Duality Advisers’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,320	Closed	-$327K	–	793
2022 Q2	$327K	Buy	+1,320	New	+$356K	0.03%	519

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return

Duality Advisers's ABMD Position: Q3 2022 in Review

Duality Advisers sold out of Abiomed Inc (ABMD) in Q3 2022, closing a stake of 1,320 shares — an estimated $327K sold.

Duality Advisers first reported a position in ABMD in Q2 2022 and held it in 1 quarter. The position peaked at $327K in Q2 2022. 517 funds tracked by Wall St. Rank hold ABMD as of Q3 2022.

Duality Advisers reported no remaining Abiomed Inc position as of Q3 2022 after selling out during the quarter.
Duality Advisers sold 1,320 Abiomed Inc shares in Q3 2022, an estimated $327K.
Duality Advisers first reported a position in Abiomed Inc in Q2 2022 and held it in 1 quarter.
Duality Advisers's Abiomed Inc position peaked at $327K in Q2 2022.
517 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2022.

Based on Duality Advisers's 13F filing for Q3 2022, filed 3 Nov 2022.